Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Long-Term Investments (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed Long-Term Investments for 6 consecutive years, with $771.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Investments rose 112.93% to $771.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $771.2 million, a 112.93% increase, with the full-year FY2025 number at $771.2 million, up 112.93% from a year prior.
  • Long-Term Investments was $771.2 million for Q4 2025 at Kymera Therapeutics, up from $473.1 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $771.2 million in Q4 2025 to a low of $45.3 million in Q2 2021.
  • A 5-year average of $205.2 million and a median of $119.4 million in 2021 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: plummeted 60.16% in 2021, then skyrocketed 489.84% in 2024.
  • Kymera Therapeutics' Long-Term Investments stood at $125.2 million in 2021, then increased by 21.65% to $152.3 million in 2022, then plummeted by 59.68% to $61.4 million in 2023, then surged by 489.84% to $362.2 million in 2024, then surged by 112.93% to $771.2 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Long-Term Investments are $771.2 million (Q4 2025), $473.1 million (Q3 2025), and $297.6 million (Q2 2025).